Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17?

Dermatol Ther. 2020 Nov;33(6):e14011. doi: 10.1111/dth.14011. Epub 2020 Jul 27.

Authors

Andrea Carugno¹, Daniele Mario Gambini¹, Francesca Raponi¹, Pamela Vezzoli¹, Elisa Robustelli Test², Marco Enrico Giovanni Arosio^{3

4}, Annapaola Callegaro^{3

4}, Paolo Sena¹

Affiliations

¹ Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
² Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
³ Microbiology and Virology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
⁴ Biobank Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects
COVID-19 / diagnosis
COVID-19 / immunology
COVID-19 / virology*
Dermatologic Agents / administration & dosage*
Dermatologic Agents / adverse effects
Drug Administration Schedule
Exanthema / diagnosis
Exanthema / immunology*
Exanthema / virology
Host-Pathogen Interactions
Humans
Male
Psoriasis / diagnosis
Psoriasis / drug therapy*
Psoriasis / immunology
Severe acute respiratory syndrome-related coronavirus / immunology
Severe acute respiratory syndrome-related coronavirus / pathogenicity*

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
secukinumab